Trastuzumab, a humanized monoclonal antibody to the HER2 protein, in combination with chemotherapy has been shown to improve disease outcomes and survival in the adjuvant setting with early-stage HER2-positive breast cancer [4–6]. This evidence concerns the gene ERBB2 and breast carcinoma.